These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 27836864)
1. Combining Molecularly Targeted Agents: Is More Always Better? Sundar R; Valeri N; Harrington KJ; Yap TA Clin Cancer Res; 2017 Mar; 23(5):1123-1125. PubMed ID: 27836864 [TBL] [Abstract][Full Text] [Related]
2. Molecular-targeted agents combination therapy for cancer: developments and potentials. Li F; Zhao C; Wang L Int J Cancer; 2014 Mar; 134(6):1257-69. PubMed ID: 23649791 [TBL] [Abstract][Full Text] [Related]
3. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Tortora G; Bianco R; Daniele G; Ciardiello F; McCubrey JA; Ricciardi MR; Ciuffreda L; Cognetti F; Tafuri A; Milella M Drug Resist Updat; 2007 Jun; 10(3):81-100. PubMed ID: 17482503 [TBL] [Abstract][Full Text] [Related]
4. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy. Pérez-Ruiz E; Etxeberria I; Rodriguez-Ruiz ME; Melero I Clin Cancer Res; 2017 Sep; 23(18):5326-5328. PubMed ID: 28790118 [TBL] [Abstract][Full Text] [Related]
5. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence? Colombo MP Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331 [TBL] [Abstract][Full Text] [Related]
6. Strategies for optimizing combinations of molecularly targeted anticancer agents. Dancey JE; Chen HX Nat Rev Drug Discov; 2006 Aug; 5(8):649-59. PubMed ID: 16883303 [TBL] [Abstract][Full Text] [Related]
7. Improving the efficacy of chemoradiation with targeted agents. Morgan MA; Parsels LA; Maybaum J; Lawrence TS Cancer Discov; 2014 Mar; 4(3):280-91. PubMed ID: 24550033 [TBL] [Abstract][Full Text] [Related]
8. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003 [TBL] [Abstract][Full Text] [Related]
12. Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors. Toska E; Baselga J Clin Cancer Res; 2016 May; 22(9):2099-101. PubMed ID: 26957555 [TBL] [Abstract][Full Text] [Related]
13. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Brechbiel J; Miller-Moslin K; Adjei AA Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036 [TBL] [Abstract][Full Text] [Related]
14. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC). Azoury SC; Gilmore RC; Shukla V Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787 [TBL] [Abstract][Full Text] [Related]
15. Safety and feasibility of targeted agent combinations in solid tumours. Park SR; Davis M; Doroshow JH; Kummar S Nat Rev Clin Oncol; 2013 Mar; 10(3):154-68. PubMed ID: 23358316 [TBL] [Abstract][Full Text] [Related]
16. The cancer stem cell gamble. Kaiser J Science; 2015 Jan; 347(6219):226-9. PubMed ID: 25593170 [No Abstract] [Full Text] [Related]
17. Combinatorial drug therapy for cancer in the post-genomic era. Al-Lazikani B; Banerji U; Workman P Nat Biotechnol; 2012 Jul; 30(7):679-92. PubMed ID: 22781697 [TBL] [Abstract][Full Text] [Related]